Search research articles
Contact Us
Filters
Showing results (21-30 of 232) with videos related to
Page
of 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2017
The <i>HRD</i> Decision<i>-</i>Which PARP Inhibitor to Use for Whom and When
Elise C Kohn, Jung-Min Lee, S Percy Ivy
Nature Reviews. Clinical Oncology
|
September 9, 2009
An overview of small-molecule inhibitors of VEGFR signaling
S Percy Ivy, Jeannette Y Wick, Bennett M Kaufman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Randomized phase II designs
Larry Rubinstein, John Crowley, Percy Ivy, et al.
Nature Reviews. Clinical Oncology
|
December 15, 2010
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Naoko Takebe, Pamela J Harris, Ronald Q Warren, et al.
Frontiers in Oncology
|
July 13, 2019
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Charles A Kunos, Jacek Capala, Elise C Kohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
S Percy Ivy, Lillian L Siu, Elizabeth Garrett-Mayer, et al.
Expert Opinion on Investigational Drugs
|
August 27, 2019
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
S Percy Ivy, Charles A Kunos, Fernanda I Arnaldez, et al.
The Lancet. Oncology
|
August 16, 2021
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants
Morgan A Casal, S Percy Ivy, Jan H Beumer, et al.
Cancer Chemotherapy and Pharmacology
|
November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
Charles A Kunos, Edward Chu, Jan H Beumer, et al.
Frontiers in Oncology
|
April 16, 2019
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
Charles A Kunos, Jacek Capala, Shanda Finnigan, et al.
Page
of 24
Search research articles
Search
Showing results (21-30 of 232) with videos related to
Sort By:
Page
of 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2017
The <i>HRD</i> Decision<i>-</i>Which PARP Inhibitor to Use for Whom and When
Elise C Kohn, Jung-Min Lee, S Percy Ivy
Nature Reviews. Clinical Oncology
|
September 9, 2009
An overview of small-molecule inhibitors of VEGFR signaling
S Percy Ivy, Jeannette Y Wick, Bennett M Kaufman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Randomized phase II designs
Larry Rubinstein, John Crowley, Percy Ivy, et al.
Nature Reviews. Clinical Oncology
|
December 15, 2010
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Naoko Takebe, Pamela J Harris, Ronald Q Warren, et al.
Frontiers in Oncology
|
July 13, 2019
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Charles A Kunos, Jacek Capala, Elise C Kohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2010
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
S Percy Ivy, Lillian L Siu, Elizabeth Garrett-Mayer, et al.
Expert Opinion on Investigational Drugs
|
August 27, 2019
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
S Percy Ivy, Charles A Kunos, Fernanda I Arnaldez, et al.
The Lancet. Oncology
|
August 16, 2021
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants
Morgan A Casal, S Percy Ivy, Jan H Beumer, et al.
Cancer Chemotherapy and Pharmacology
|
November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
Charles A Kunos, Edward Chu, Jan H Beumer, et al.
Frontiers in Oncology
|
April 16, 2019
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
Charles A Kunos, Jacek Capala, Shanda Finnigan, et al.
Page
of 24